JP2009531031A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009531031A5 JP2009531031A5 JP2009501604A JP2009501604A JP2009531031A5 JP 2009531031 A5 JP2009531031 A5 JP 2009531031A5 JP 2009501604 A JP2009501604 A JP 2009501604A JP 2009501604 A JP2009501604 A JP 2009501604A JP 2009531031 A5 JP2009531031 A5 JP 2009531031A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- fragment
- tumor cell
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 47
- 239000012634 fragment Substances 0.000 claims 33
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 241000124008 Mammalia Species 0.000 claims 15
- 238000001514 detection method Methods 0.000 claims 11
- 210000004881 tumor cell Anatomy 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 9
- 229940127121 immunoconjugate Drugs 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 230000000259 anti-tumor effect Effects 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 102100030377 Endoplasmic reticulum metallopeptidase 1 Human genes 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 6
- 108090000790 Enzymes Proteins 0.000 claims 6
- 102100021613 Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase Human genes 0.000 claims 6
- 101001063315 Homo sapiens Endoplasmic reticulum metallopeptidase 1 Proteins 0.000 claims 6
- 101001044070 Homo sapiens Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase Proteins 0.000 claims 6
- 101000638481 Homo sapiens Protein THEM6 Proteins 0.000 claims 6
- 101000713169 Homo sapiens Solute carrier family 52, riboflavin transporter, member 2 Proteins 0.000 claims 6
- -1 LOC157378 Proteins 0.000 claims 6
- 102100031255 Protein THEM6 Human genes 0.000 claims 6
- 102100036862 Solute carrier family 52, riboflavin transporter, member 2 Human genes 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 101000857740 Homo sapiens Probable G-protein coupled receptor 160 Proteins 0.000 claims 5
- 102100025346 Probable G-protein coupled receptor 160 Human genes 0.000 claims 5
- 102000012987 SLC1A5 Human genes 0.000 claims 5
- 108060002241 SLC1A5 Proteins 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 231100000765 toxin Toxicity 0.000 claims 4
- 239000003053 toxin Substances 0.000 claims 4
- 108700012359 toxins Proteins 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 claims 2
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 claims 2
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 claims 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 102000009133 Arylsulfatases Human genes 0.000 claims 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 1
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 1
- 108090000204 Dipeptidase 1 Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 229930126263 Maytansine Natural products 0.000 claims 1
- 231100000757 Microbial toxin Toxicity 0.000 claims 1
- 102000005348 Neuraminidase Human genes 0.000 claims 1
- 108010006232 Neuraminidase Proteins 0.000 claims 1
- 108010073038 Penicillin Amidase Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 231100000742 Plant toxin Toxicity 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 102000036693 Thrombopoietin Human genes 0.000 claims 1
- 108010041111 Thrombopoietin Proteins 0.000 claims 1
- 150000001224 Uranium Chemical group 0.000 claims 1
- 229910052770 Uranium Inorganic materials 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 231100000659 animal toxin Toxicity 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 102000006635 beta-lactamase Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 229930195731 calicheamicin Natural products 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000001839 endoscopy Methods 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- GMBVGUFXJFKNMR-UHFFFAOYSA-N gadolinium Chemical compound [Gd].[Gd].[Gd] GMBVGUFXJFKNMR-UHFFFAOYSA-N 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 108060007951 sulfatase Proteins 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78570406P | 2006-03-23 | 2006-03-23 | |
| PCT/US2007/007382 WO2007109376A2 (en) | 2006-03-23 | 2007-03-22 | Anti-tumor cell antigen antibody therapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009531031A JP2009531031A (ja) | 2009-09-03 |
| JP2009531031A5 true JP2009531031A5 (https=) | 2011-03-17 |
Family
ID=38523127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009501604A Pending JP2009531031A (ja) | 2006-03-23 | 2007-03-22 | 抗−腫瘍細胞抗原抗体療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20110135570A1 (https=) |
| EP (7) | EP2389951A1 (https=) |
| JP (1) | JP2009531031A (https=) |
| KR (1) | KR20080110810A (https=) |
| CN (1) | CN101437536A (https=) |
| AU (1) | AU2007227224A1 (https=) |
| CA (1) | CA2647107A1 (https=) |
| IL (1) | IL194137A0 (https=) |
| MA (1) | MA30346B1 (https=) |
| MX (1) | MX2008012013A (https=) |
| NO (1) | NO20084479L (https=) |
| RU (1) | RU2008141912A (https=) |
| SG (1) | SG170728A1 (https=) |
| WO (1) | WO2007109376A2 (https=) |
| ZA (1) | ZA200808128B (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8268592B2 (en) | 2008-07-17 | 2012-09-18 | Kyowa Hakko Kirin Co., Ltd | Anti-system ASC amino acid transporter 2 (ASCT2) antibody |
| WO2011063127A1 (en) * | 2009-11-18 | 2011-05-26 | University Of Medicine And Dentistry Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| WO2011051277A1 (en) * | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Breast tumor markers and methods of use thereof |
| US8921058B2 (en) | 2009-10-26 | 2014-12-30 | Externautics Spa | Prostate tumor markers and methods of use thereof |
| US10288617B2 (en) | 2009-10-26 | 2019-05-14 | Externautics Spa | Ovary tumor markers and methods of use thereof |
| US9849192B2 (en) | 2009-11-18 | 2017-12-26 | Rutgers, The State University Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| KR20120115511A (ko) * | 2010-01-15 | 2012-10-18 | 교와 핫꼬 기린 가부시키가이샤 | 항시스템 ａｓｃ 아미노산 트랜스포터 ２（ａｓｃｔ２） 항체 |
| JP5805190B2 (ja) | 2010-08-19 | 2015-11-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 療法用モノクローナル抗体に結合する抗体の測定のためのアッセイ |
| WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
| JP6499079B2 (ja) * | 2012-11-13 | 2019-04-10 | バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ | クローディンを発現するガン疾患を処置するための剤 |
| JP2016029335A (ja) * | 2012-12-17 | 2016-03-03 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 大腸がんの判定方法 |
| RS61778B1 (sr) | 2013-05-06 | 2021-06-30 | Scholar Rock Inc | Kompozicije i postupci za modulaciju faktora rasta |
| FI3218005T3 (fi) | 2014-11-12 | 2023-03-31 | Seagen Inc | Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä |
| US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| CN108025071B (zh) * | 2015-09-17 | 2022-11-01 | 斯克利普斯研究院 | 双重可变结构域免疫缀合物及其用途 |
| CN106554962B (zh) * | 2015-09-30 | 2021-06-04 | 中国科学院上海药物研究所 | 过表达gpr160的癌症的预防、诊断和治疗 |
| MY192146A (en) | 2015-11-10 | 2022-08-01 | Medimmune Llc | Binding molecules specific for asct2 and uses thereof |
| CA3002097A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| CA3017958C (en) | 2016-03-18 | 2024-03-12 | Rutgers, The State University Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties |
| CN109641038A (zh) * | 2016-07-01 | 2019-04-16 | 小利兰·斯坦福大学理事会 | 靶向细胞表面编辑的共轭物 |
| AU2017359155A1 (en) * | 2016-11-10 | 2019-06-13 | Medimmune, Llc | Binding molecules specific for ASCT2 and uses thereof |
| WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| GB201701332D0 (en) * | 2017-01-26 | 2017-03-15 | Tc Biopharm Ltd | Immune cells with modified metabolism and their use thereof |
| WO2018160909A1 (en) | 2017-03-03 | 2018-09-07 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| KR101899426B1 (ko) * | 2017-05-25 | 2018-09-17 | (주)큐브바이오 | 종양 진단을 위한 퓨린 대사체 하이포잔틴 및 잔틴 농도 분석용 효소 조성물 |
| EP3646010A4 (en) | 2017-06-27 | 2020-11-11 | Qcdx, Llc | QUANTITATIVE LIQUID BIOPSY DIAGNOSIS SYSTEM AND METHODS |
| EP3735458A4 (en) | 2018-01-03 | 2022-04-27 | Palleon Pharmaceuticals Inc. | RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN111366547A (zh) * | 2018-12-26 | 2020-07-03 | 贵州中烟工业有限责任公司 | 一种用连续流动法测定烟草或烟草制品中α-氨基氮的检测方法 |
| CN110055249B (zh) * | 2019-03-19 | 2021-10-15 | 江苏医药职业学院 | 降低THEM6基因表达的siRNA、重组载体及其应用 |
| KR102242900B1 (ko) * | 2019-08-07 | 2021-04-22 | 연세대학교 산학협력단 | Slc1a5 전사물 변이체를 이용한 항암용 조성물, 항암제 스크리닝 방법 및 암 진단 방법 |
| EP4087389A4 (en) * | 2020-01-09 | 2024-02-21 | Arizona Board of Regents on behalf of Arizona State University | Antibodies and method of producing antibodies |
| CN115372604B (zh) * | 2022-07-07 | 2023-03-28 | 山东第一医科大学附属省立医院(山东省立医院) | 一种用于预测肿瘤患者免疫治疗疗效的标志物及其应用 |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| KR0154872B1 (ko) | 1987-12-21 | 1998-10-15 | 로버트 에이. 아미테이지 | 발아하는 식물종자의 아크로박테리움 매개된 형질전환 |
| ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| ES2038579T3 (es) | 1989-04-28 | 1997-02-16 | Rhein Biotech Proz & Prod Gmbh | Celulas de levadura del genero schwanniomyces. |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| FR2678930B1 (fr) | 1991-07-10 | 1995-01-13 | Rhone Poulenc Rorer Sa | Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii. |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| US5770358A (en) | 1991-09-18 | 1998-06-23 | Affymax Technologies N.V. | Tagged synthetic oligomer libraries |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| CA2124087C (en) | 1991-11-22 | 2002-10-01 | James L. Winkler | Combinatorial strategies for polymer synthesis |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| WO1993016177A1 (en) | 1992-02-11 | 1993-08-19 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| CA2150803C (en) | 1992-12-02 | 2006-01-31 | Henry Auer | Controlled release growth hormone containing microspheres |
| PT616812E (pt) | 1993-03-24 | 2000-04-28 | Berlex Biosciences | Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| PT779806E (pt) | 1994-09-09 | 2001-02-28 | Takeda Chemical Industries Ltd | Preparacao de libertacao sustentada contendo um sal metalico de um peptido |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| PT831787E (pt) | 1995-06-07 | 2002-02-28 | Alkermes Inc | Composicao para libertacao sustentada da hormona de crescimento humano |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| ES2434840T3 (es) | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| US6458939B1 (en) | 1996-03-15 | 2002-10-01 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
| US6387638B1 (en) | 1997-02-10 | 2002-05-14 | Genentech, Inc. | Heregulin variants |
| DE69829402T2 (de) | 1997-10-31 | 2006-04-13 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | Expressionsprofile in adulten und fötalen organen |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| WO2003009814A2 (en) * | 2001-07-25 | 2003-02-06 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer |
| DE60238143D1 (de) * | 2001-09-18 | 2010-12-09 | Genentech Inc | Zusammensetzungen und verfahren für die diagnose von tumoren |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| US7504222B2 (en) * | 2001-10-31 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| AU2002359777A1 (en) * | 2001-12-21 | 2003-07-30 | Idec Pharmaceuticals Corporation | Genes overexpresses by ovarian cancer and their use in developing novel therapeutics especially antibodies |
| US20040005644A1 (en) * | 2002-02-28 | 2004-01-08 | Su Yan A. | Method and composition for detection and treatment of breast cancer |
| JP4557497B2 (ja) * | 2002-03-03 | 2010-10-06 | ローム・アンド・ハース・エレクトロニック・マテリアルズ，エル．エル．シー． | シランモノマー及びポリマーを製造する方法及びそれを含むフォトレジスト組成物 |
| MXPA05011811A (es) | 2003-05-20 | 2006-02-17 | Immunogen Inc | Agentes citotoxicos mejorados que comprenden nuevos maitansinoides. |
| US20050119210A1 (en) * | 2003-05-20 | 2005-06-02 | Xiaobing Be | Compositions and methods for diagnosing and treating cancers |
| DE602004017726D1 (de) | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| CA2534639C (en) * | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2005026325A2 (en) * | 2003-09-10 | 2005-03-24 | Surromed, Inc, | Bivalent targeting of cell surfaces |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| EP2311985A1 (en) * | 2005-07-27 | 2011-04-20 | Oncotherapy Science, Inc. | Sirna for treating esophageal cancer |
-
2007
- 2007-03-22 RU RU2008141912/13A patent/RU2008141912A/ru not_active Application Discontinuation
- 2007-03-22 US US12/225,353 patent/US20110135570A1/en not_active Abandoned
- 2007-03-22 EP EP11167460A patent/EP2389951A1/en not_active Withdrawn
- 2007-03-22 AU AU2007227224A patent/AU2007227224A1/en not_active Abandoned
- 2007-03-22 KR KR1020087025032A patent/KR20080110810A/ko not_active Abandoned
- 2007-03-22 CA CA002647107A patent/CA2647107A1/en not_active Abandoned
- 2007-03-22 EP EP11167328A patent/EP2389947A1/en not_active Withdrawn
- 2007-03-22 CN CNA2007800161919A patent/CN101437536A/zh active Pending
- 2007-03-22 SG SG201101875-1A patent/SG170728A1/en unknown
- 2007-03-22 EP EP11167316A patent/EP2389946A1/en not_active Withdrawn
- 2007-03-22 EP EP11167456A patent/EP2389949A1/en not_active Withdrawn
- 2007-03-22 EP EP11167459A patent/EP2389950A1/en not_active Withdrawn
- 2007-03-22 EP EP07773740A patent/EP2004221A2/en not_active Withdrawn
- 2007-03-22 JP JP2009501604A patent/JP2009531031A/ja active Pending
- 2007-03-22 WO PCT/US2007/007382 patent/WO2007109376A2/en not_active Ceased
- 2007-03-22 MX MX2008012013A patent/MX2008012013A/es unknown
- 2007-03-22 EP EP11167453A patent/EP2389948A1/en not_active Withdrawn
-
2008
- 2008-09-16 IL IL194137A patent/IL194137A0/en unknown
- 2008-09-22 ZA ZA200808128A patent/ZA200808128B/xx unknown
- 2008-10-20 MA MA31311A patent/MA30346B1/fr unknown
- 2008-10-23 NO NO20084479A patent/NO20084479L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009531031A5 (https=) | ||
| RU2008141912A (ru) | Противоопухолевые лекарства на основе антител к клеточным антигенам | |
| Altunay et al. | HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging | |
| Boswell et al. | Effects of charge on antibody tissue distribution and pharmacokinetics | |
| Senter et al. | Selective activation of anticancer prodrugs by monoclonal antibody–enzyme conjugates | |
| Khaibullina et al. | Pulsed high-intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice | |
| RU2423382C1 (ru) | Композиции и способы диагностики и лечения опухоли | |
| EP3643726A1 (en) | Anti-her2 nanobody and coding sequence and use thereof | |
| CN106999606B (zh) | 抗体药物偶联物 | |
| JPS63218628A (ja) | 抗体接合体およびその調製方法 | |
| JP2006513695A5 (https=) | ||
| JPH06500563A (ja) | 調節された浄化時間を有する修飾抗体 | |
| JP2006507803A5 (https=) | ||
| CN107735110A (zh) | 纳米粒子免疫偶联物 | |
| US20120034158A1 (en) | Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis corresponding compositions and kits | |
| Quiles et al. | Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy | |
| Kwon et al. | 64Cu-labeled trastuzumab fab-PEG24-EGF radioimmunoconjugates bispecific for HER2 and EGFR: pharmacokinetics, biodistribution, and tumor imaging by PET in comparison to monospecific agents | |
| WO2016016021A1 (en) | Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer | |
| US20190106507A1 (en) | Antibody-drug conjugates containing anti-globo h antibodies and uses thereof | |
| CN118307673A (zh) | Nectin-4单域抗体及其用途 | |
| JP2025522547A (ja) | Ｃｄ７３を標的とするナノ抗体およびナノ抗体－薬物複合体、その製造方法と使用 | |
| Magro et al. | Target engagement of an anti-MT1-MMP antibody for triple-negative breast cancer PET imaging and beta therapy | |
| Liu et al. | Epidermal growth factor receptor–targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab | |
| CN118667006A (zh) | 靶向ror1的抗体、包含其的抗体偶联药物、制备方法和用途 | |
| Facca et al. | Imaging of HER2-positive tumors in NOD/SCID mice with Pertuzumab Fab-hexahistidine peptide immunoconjugates labeled with [99mTc]-(I)-Tricarbonyl complex |